Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Vermeire, Séverine; D’Haens, Geert; Baert, Filip; Danese, Silvio; Kobayashi, Taku; V. Loftus, Edward; Bhatia, Siddharth; Agboton, Christian; Rosario, Maria; Chen, Chunlin; Zhang, Wenwen; Kisfalvi, Krisztina; J. Sandborn, William

doi:10.1093/ecco-jcc/jjab133

Public

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Published in Journal of Crohn s and Colitis • Aug 16, 2021

Authors:

Séverine Vermeire

Geert D’Haens

Filip Baert

Abstract

BACKGROUND AND AIMS: To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn's disease [CD]. METHODS: Following open-label ve...

Subject

Medicine

Vedolizumab

Crohn's disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!